Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting

Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting

Abstract Introduction Elexacaftor/tezacaftor/ivacaftor (ETI) has been shown to substantially improve clinical outcomes among people living with cystic fibrosis (pwCF). The impact of ETI on health care resource utilization in the context of universal health care is largely unknown. We aimed to assess...

Full description

Saved in:
Bibliographic Details
Main Authors: Hans Kristian Råket, Mikkel Zöllner Ankarfeldt, Joanna Nan Wang, Tacjana Pressler, Søren Jensen-Fangel, Tavs Qvist, Daniel Faurholt-Jepsen, Espen Jimenez-Solem, Janne Petersen, Camilla Bjørn Jensen, on behalf of the TransformCF Study Group
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Pulmonary Therapy
Subjects:
Cystic fibrosis
Health care resource utilization
Hospitalization
Universal health care
Elexacaftor/tezacaftor/ivacaftor
Online Access:https://doi.org/10.1007/s41030-025-00287-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items